Roche outlines AI labs. Roche Holding stock costs EUR 374.45 ahead of October 22 results

Published on 10/02/2026 at 13:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Phase III success exceeded 80.00 percent in 2026 versus 65.00 percent. Roche Holding stock costs EUR 374.45 on October 2, 2026 after EUR 371.38.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding stock (ISIN CH1499059983) was trading at EUR 374.45 at Lang & Schwarz on October 2, 2026 at 1:14 p.m. CEST. As Reuters reported on September 28, 2026, Roche outlined plans for autonomous artificial intelligence laboratories and said its Phase III success rate rose above 80.00 percent in 2026 from 65.00 percent in 2025.

AI turns into a pipeline metric

The figures give Roche's artificial intelligence strategy a measurable operating dimension. Reuters reported that 40.00 percent of pipeline decisions from the fourth quarter of 2025 through the second quarter of 2026 included a tracked AI or computational contribution.

Roche also said its Target Nexus tool is on track to contribute to 80.00 percent of research portfolio decisions by the end of 2026. The company is targeting up to 20 new molecular entities by 2030, while about CHF 2.0 billion of research and development savings are set for reallocation to programs and productivity initiatives by 2026, Reuters said on September 28, 2026.

Pharma Day raises execution stakes

Roche's September 28, 2026 Pharma Day placed pipeline productivity beside late-stage development success. The shift matters because a higher Phase III conversion rate can improve the value of research spending, but the commercial payoff still depends on regulatory decisions and eventual launches.

The company reported core earnings per share growth of 11.00 percent at constant exchange rates in fiscal year 2025, reaching CHF 19.46 on a diluted basis, according to Roche. Roche also said 39 million patients received its medicines in fiscal year 2025 and that 31 billion diagnostic tests were delivered worldwide.

October 22 sets the next test

Roche has scheduled its third-quarter sales presentation for October 22, 2026, at 2:00 p.m. CEST, according to the company's investor calendar. That date gives the market a near-term checkpoint for sales momentum and evidence that the pipeline strategy is translating into operating performance. Roche's market capitalization was USD 304.9 billion as of October 1, 2026.

Roche Holding stock stays in trading

Roche Holding stock was trading at EUR 374.45 at Lang & Schwarz on October 2, 2026 at 1:14 p.m. CEST, plus 0.83 percent versus the Lang & Schwarz prior close of EUR 371.38 on October 1, 2026. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.